Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
Conditions: Small Cell Lung Cancer
Age: Between 18 - 80 Years
Gender: Male or Female
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required